145 related articles for article (PubMed ID: 31389685)
21. Structural and functional profiling of the human histone methyltransferase SMYD3.
Foreman KW; Brown M; Park F; Emtage S; Harriss J; Das C; Zhu L; Crew A; Arnold L; Shaaban S; Tucker P
PLoS One; 2011; 6(7):e22290. PubMed ID: 21779408
[TBL] [Abstract][Full Text] [Related]
22. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Sun J; Shi F; Yang N
ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
[TBL] [Abstract][Full Text] [Related]
23. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
24. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
25. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Silva FP; Hamamoto R; Kunizaki M; Tsuge M; Nakamura Y; Furukawa Y
Oncogene; 2008 Apr; 27(19):2686-92. PubMed ID: 17998933
[TBL] [Abstract][Full Text] [Related]
26. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
Yoshioka Y; Suzuki T; Matsuo Y; Nakakido M; Tsurita G; Simone C; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Oncotarget; 2016 Nov; 7(46):75023-75037. PubMed ID: 27626683
[TBL] [Abstract][Full Text] [Related]
27. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
[TBL] [Abstract][Full Text] [Related]
28. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
29. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
30. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
31. Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?
Zhang Y; Li C; Yang Z
Front Mol Biosci; 2019; 6():121. PubMed ID: 31737645
[TBL] [Abstract][Full Text] [Related]
32. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.
Zhang L; Jin Y; Yang H; Li Y; Wang C; Shi Y; Wang Y
Carcinogenesis; 2019 Dec; 40(12):1492-1503. PubMed ID: 31002112
[TBL] [Abstract][Full Text] [Related]
33. Histone methyltransferase Smyd3 regulates early embryonic lineage commitment in mice.
Suzuki S; Nozawa Y; Tsukamoto S; Kaneko T; Imai H; Minami N
Reproduction; 2015 Jul; 150(1):21-30. PubMed ID: 25918436
[TBL] [Abstract][Full Text] [Related]
34. Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription.
Chen J; He Z; Yuan Y; Huang F; Luo B; Zhang J; Pan T; Zhang H; Zhang J
Emerg Microbes Infect; 2019; 8(1):1347-1360. PubMed ID: 31516086
[TBL] [Abstract][Full Text] [Related]
35. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
[TBL] [Abstract][Full Text] [Related]
36. Preparation, Biochemical Analysis, and Structure Determination of SET Domain Histone Methyltransferases.
Bergamin E; Couture JF
Methods Enzymol; 2016; 573():209-40. PubMed ID: 27372755
[TBL] [Abstract][Full Text] [Related]
37. SET and MYND domain containing protein 3 in cancer.
Huang L; Xu AM
Am J Transl Res; 2017; 9(1):1-14. PubMed ID: 28123630
[TBL] [Abstract][Full Text] [Related]
38. C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
Brown MA; Foreman K; Harriss J; Das C; Zhu L; Edwards M; Shaaban S; Tucker H
Oncotarget; 2015 Feb; 6(6):4005-19. PubMed ID: 25738358
[TBL] [Abstract][Full Text] [Related]
39. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
[TBL] [Abstract][Full Text] [Related]
40. The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.
Fittipaldi R; Floris P; Proserpio V; Cotelli F; Beltrame M; Caretti G
Cells; 2021 May; 10(5):. PubMed ID: 34069776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
